Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE: Abbott-Depakote Shareholder Derivative Litigation
Case Number:
1:11-cv-08114
Court:
Nature of Suit:
160(Contract: Stockholders Suits)
Multi Party Litigation:
Derivative Litigation
Judge:
Firms
- Anderson & Wanca
- Freed Kanner
- Hagens Berman
- Jones Day
- Kessler Topaz
- Kirkland & Ellis
- Robbins Geller
- Shaw Fishman
- Spector Roseman
Companies
Sectors & Industries:
-
March 07, 2014
Abbott, Shareholders Agree To Settle Depakote Marketing Suit
Abbott Laboratories shareholders asked an Illinois federal judge on Thursday to bless a settlement resolving a derivative suit that alleged Abbott's directors cost the company $1.6 billion because they did nothing to stop the marketing of its anti-seizure drug Depakote for off-label uses.
-
June 05, 2013
Abbott Can't Kick Investor Suit Over Depakote Marketing
A federal judge on Wednesday refused to toss a shareholder derivative suit against Abbott Laboratories, finding the plaintiffs had adequately argued Abbott's directors knew the company was in trouble for marketing off-label uses for the anti-seizure drug Depakote but did nothing, costing the company $1.6 billion.